TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21717444

Group type: EXPERIMENTAL
Intervention: Cenersen plus idarubicin (with or without cytarabine)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cenersen inhibitors (acetaminophen and/or high dose antioxidants)
Number of subjects: 53
Study: 19608835

Group type: EXPERIMENTAL
Intervention: Extended perineural ropivacaine infusion (n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal saline (control group, n = 23)
Number of subjects: 47
Study: 17499389

Group type: EXPERIMENTAL
Intervention: Alcohol-based spray sunscreen
Number of subjects: 139

Group type: COMPARATOR
Intervention: Other sunscreens (not specified)
Number of subjects: 139
Study: 15228197

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (body height, weight, skinfolds, girths, lengths, breadths/lengths)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Nonlinear discriminant analysis
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Anthropometric characteristics
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Length and breadth/length parameters
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Skinfold thicknesses
Number of subjects: 361
Study: 11864853

Group type: COMPARATOR
Intervention: Saturated fat diet (17% palm oil)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet (20.9% olive oil)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: n-6 polyunsaturated fat diet (12.5% sunflower oil)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fat diet (sunflower oil + 4-4.5 g fish oil/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diets
Number of subjects: 41
Study: 11279920

Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine (10 mg twice daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: flunarizine (5 mg once daily)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine
Number of subjects: 135

Group type: COMPARATOR
Intervention: flunarizine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine and flunarizine
Number of subjects: 135
Study: 7778155

Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aminosidine 12 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Aminosidine 6 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall success rate with aminosidine 12 mg/kg/d
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall success rate with aminosidine 6 mg/kg/d
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of aminosidine 12 mg/kg/d vs 6 mg/kg/d
Number of subjects: 96
Study: 2182566

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 6162348

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream applied under occlusive dressing for 60 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 0
Study: 31130260

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 648

Group type: COMPARATOR
Intervention: Continued methotrexate
Number of subjects: 648
Study: 29234808

Group type: EXPERIMENTAL
Intervention: Levothyroxine (25-μg/d or 50-μg/d, titrated according to TSH levels during pregnancy)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control (no levothyroxine treatment)
Number of subjects: 600
Study: 26251480

Group type: EXPERIMENTAL
Intervention: Targeted multimodal spine-strengthening exercise intervention (3 times a week for 6 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Targeted multimodal spine-strengthening exercise intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monthly health education meetings and monthly calls from the study coordinator
Number of subjects: 100
Study: 25844062

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no further training)
Number of subjects: 10
Study: 22782483

Group type: EXPERIMENTAL
Intervention: 10-Hz stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1-Hz stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 60
Study: 19588221

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) at 10 Hz over left PMd and DLPFC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo stimulation over occipital cortex (OCC)
Number of subjects: 10
Study: 17323666

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 180
Study: 14742609

Group type: COMPARATOR
Intervention: 25 mg of quetiapine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50 mg/day of quetiapine (open label phase)
Number of subjects: 9
Study: 11851736

Group type: EXPERIMENTAL
Intervention: Lower leg casting prior to BTX‐A injections
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Casting immediately after BTX‐A injections
Number of subjects: 34
Study: 9870539

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Implant prostheses
Number of subjects: 120
Study: 7986398

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) in HIV-infected patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) in seronegative volunteers
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Zidovudine monophosphate (ZDV-MP) in HIV-infected patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Zidovudine triphosphate (ZDV-TP) in both groups
Number of subjects: 17
Study: 2680476

Group type: EXPERIMENTAL
Intervention: Oral glucose (75 g)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Insulin infusion (plateau insulin concentration 50‐55 mU/l)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Overnight fast
Number of subjects: 13
Study: 30512231

Group type: EXPERIMENTAL
Intervention: Single-pole position
Number of subjects: 94

Group type: COMPARATOR
Intervention: Double-pole position
Number of subjects: 94
Study: 29170463

Group type: EXPERIMENTAL
Intervention: Luxury brand labels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-luxury brand labels
Number of subjects: 0
Study: 26599634

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-Dapsone (CD)
Number of subjects: 0
Study: 23181592

Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Ingesting ≥1 hypertension medication at bedtime
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Changes in asleep systolic BP mean
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Asleep BP mean adjusted by awake mean
Number of subjects: 3344
Study: 22152013

Group type: EXPERIMENTAL
Intervention: High-dose erythropoiesis-stimulating agents (ESA) (≥ 1 μg/kg/week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual-dose erythropoiesis-stimulating agents (ESA) (< 1 μg/kg/week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher ESA dose (per μcg/kg/week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-dose erythropoiesis-stimulating agents (ESA)
Number of subjects: 32
Study: 19329456

Group type: EXPERIMENTAL
Intervention: Micrometric bioactive glass slurry
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nanometric bioactive glass slurry
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hybrid bioactive glass slurry
Number of subjects: 12
Study: 17115882

Group type: EXPERIMENTAL
Intervention: Reflecting interview intervention group
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 24
Study: 15156393

Group type: EXPERIMENTAL
Intervention: Bupivacaine 80 mg in 25 cc of saline
Number of subjects: 44
Study: 11305844

Group type: EXPERIMENTAL
Intervention: Generic clozapine (Zenith Goldline Pharmaceuticals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozaril (Novartis Pharmaceuticals)
Number of subjects: 0
Study: 9438889

Group type: EXPERIMENTAL
Intervention: Gravity flow administration of local anesthetic (Group 1)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Bolus injection (Group 2)
Number of subjects: 600
Study: 7705775

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily for 4 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (nontreatment)
Number of subjects: 31
Study: 2650694

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil providing about 3.2 g n-3 fatty acids per day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil
Number of subjects: 39
Study: 278737

Group type: EXPERIMENTAL
Intervention: Toothpaste containing detergents (high content of surface active substances)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (not specified in the abstract)
Number of subjects: 98
Study: 31867715

Group type: EXPERIMENTAL
Intervention: Carbetocin (ED90 estimated as 62.9 μg using truncated Dixon and Mood method)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbetocin (ED90 estimated as 68 μg using isotonic regression method)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 30
Study: 31141159

Group type: EXPERIMENTAL
Intervention: Oral glibenclamide (GBC)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no GBC or other sulfonylureas prior to stroke or after hospitalization)
Number of subjects: 213
Study: 27040458

Group type: EXPERIMENTAL
Intervention: Standard corneal crosslinking (CXL)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Transepithelial iontophoresis-assisted CXL
Number of subjects: 149
Study: 23875809

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified doogh (DD; containing 150 mg calcium and 500 IU vitamin D/250 mL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D-fortified doogh (CDD; containing 250 mg calcium and 500 IU vitamin D/250 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plain doogh (PD; containing 150 mg calcium and no detectable vitamin D/250 mL)
Number of subjects: 90
Study: 21991736

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19797554

Group type: EXPERIMENTAL
Intervention: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride) applied before in-office bleaching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel applied before in-office bleaching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 16895889

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (daily capsule containing 120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 µg Se, and 20 mg Zn)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Baseline beta-carotene dietary intakes and plasma concentrations
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Baseline plasma vitamin C
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Baseline plasma selenium
Number of subjects: 3146
Study: 14670572

Group type: EXPERIMENTAL
Intervention: Target saliency manipulation in visual search tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task difficulty manipulation in visual search tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 0
Study: 11712091

Group type: EXPERIMENTAL
Intervention: 30 mg primaquine daily for 20 weeks
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 8703810

Group type: EXPERIMENTAL
Intervention: Tucaresol (oral doses; loading dose of 800 mg or 1200 mg for the first 4 days, followed by maintenance doses of 200 mg or 300 mg for the next 6 days; subsequent cohorts received 300 mg daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1678631

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Billroth I gastroduodenostomy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 6861819

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (CRE above 1,400 reu)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cystectomy alone (no preoperative irradiation)
Number of subjects: 44
Study: 31818048

Group type: EXPERIMENTAL
Intervention: Abdominal vibration stimulation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (not specified in detail)
Number of subjects: 300
Study: 31409366

Group type: EXPERIMENTAL
Intervention: WNJ SJOV Group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 100
Study: 28253863

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h after a loading dose of 1.0 μg/kg for 10 min)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Propofol (1.6 μg/ml target effect site concentration)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combined use of propofol and dexmedetomidine (M group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Propofol (P group)
Number of subjects: 87
Study: 26844873

Group type: EXPERIMENTAL
Intervention: Octreotide LAR (40 mg, n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 27
Study: 24954822

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Supportive Nondirective Therapy (SNDT)
Number of subjects: 217
Study: 22089179

Group type: EXPERIMENTAL
Intervention: Yoga exercise group (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No exercise control group (n = 8)
Number of subjects: 16
Study: 18976370

Group type: EXPERIMENTAL
Intervention: ErythroSave
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (ordinary syringes)
Number of subjects: 20
Study: 17598783

Group type: EXPERIMENTAL
Intervention: RELATE with therapist assistance
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RELATE without therapist assistance
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 15726912

Group type: COMPARATOR
Intervention: Menotropins only (group A)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Menotropins plus mini-dose GnRH-analog (600 microg/day) (group B)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Menotropins plus standard dose GnRH-analog (900 microg/day) (group C)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: GnRH-analog included in the protocol (groups B and C)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 219
Study: 12043876

Group type: EXPERIMENTAL
Intervention: CT‐5 microsurgical ultrasonic instrument (stainless steel)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: KiS microsurgical ultrasonic instrument (zirconium nitride-coated)
Number of subjects: 40
Study: 9807605

Group type: EXPERIMENTAL
Intervention: Ro 48-6791
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 76
Study: 7631946

Group type: EXPERIMENTAL
Intervention: 2% glucose in lactated Ringer's solution (D2LR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% glucose in lactated Ringer's solution (D5LR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR) alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucose-free infusion (LR group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% glucose in lactated Ringer's solution (D2LR) and 5% glucose in lactated Ringer's solution (D5LR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucose-free solution (LR group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 2189428

Group type: EXPERIMENTAL
Intervention: No gown (experimental group)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Gown (control group)
Number of subjects: 452
Study: 421509

Group type: EXPERIMENTAL
Intervention: dry-skin (triethanolamine) soap
Number of subjects: 50

Group type: COMPARATOR
Intervention: hard-milled soap
Number of subjects: 50
Study: 31164366

Group type: EXPERIMENTAL
Intervention: Systematic Tool to Reduce Inappropriate Prescribing (STRIP) intervention
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: STRIP intervention
Number of subjects: 4
Study: 28590244

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg administered as two 1‐mL subcutaneous injections every 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg administered as one 2‐mL injection delivered over different rates (10 seconds, 1 minute, 12 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg administered by different injection rates
Number of subjects: 60
Study: 26446596

Group type: EXPERIMENTAL
Intervention: BP-BES
Number of subjects: 3235

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 3235
Study: 22362618

Group type: EXPERIMENTAL
Intervention: Individually delivered personalized alcohol feedback
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Electronically delivered personalized alcohol feedback
Number of subjects: 173

Group type: COMPARATOR
Intervention: Group-delivered personalized alcohol feedback
Number of subjects: 173
Study: 21336615

Group type: EXPERIMENTAL
Intervention: Kaolin-impregnated pads
Number of subjects: 118

Group type: COMPARATOR
Intervention: Manual compression without kaolin-impregnated pads
Number of subjects: 118
Study: 19432292

Group type: EXPERIMENTAL
Intervention: Drug acquisition
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Medical services
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Medical devices
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Loss of productivity and absentism
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Total costs
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sickness absence days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Hospital treatment days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drug sales
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Insulins and analogs sales
Number of subjects: 99
Study: 16899650

Group type: EXPERIMENTAL
Intervention: Bedtime Pass Program (BPP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Monitoring Control
Number of subjects: 19
Study: 14962353

Group type: EXPERIMENTAL
Intervention: Combined monoamine depletion (CMD) condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Balanced control (B) condition
Number of subjects: 10
Study: 11491193

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9387943

Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study: 8191660

Group type: EXPERIMENTAL
Intervention: He‐Ne laser treatment (wavelength 0.63 microns, light spot diameter 5 mm, energy 2 mWt, session duration 240 sec, 10 sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (17 eyes of the same patients)
Number of subjects: 23
Study: 3321890

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution with powdered rice and Dal moong
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard WHO oral rehydration salt solution (ORS)
Number of subjects: 60
Study: 30023053

Group type: EXPERIMENTAL
Intervention: Integrated post‐partum family planning and maternal and newborn health (PPFP‐MNH) interventions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Maternal and newborn health (MNH) interventions only
Number of subjects: 8
Study: 27012873

Group type: EXPERIMENTAL
Intervention: 10 g oral glucose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 25 g oral glucose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PostOP
Number of subjects: 32

Group type: COMPARATOR
Intervention: LC and OC
Number of subjects: 32
Study: 25912695

Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: UFH/warfarin (control treatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 80

Group type: COMPARATOR
Intervention: UFH/warfarin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Apixaban and UFH/warfarin
Number of subjects: 80
Study: 21598237

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy to postchemotherapy tumor extent
Number of subjects: 85

Group type: COMPARATOR
Intervention: Thoracic radiotherapy to prechemotherapy tumor extent (Control)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both arms omitted elective nodal irradiation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 85
Study: 20651000

Group type: EXPERIMENTAL
Intervention: Detection of mental disorders plus feedback to individuals and caregivers
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 836